COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study
| Autor: | Henrik Rudolf, Lutz Uflacker, Oktay Hökelekli, Sören Gatermann, Anke Hildebrandt |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Health Personnel 010501 environmental sciences Antibodies Viral 01 natural sciences Article Antibodies 03 medical and health sciences Young Adult 0302 clinical medicine Risk Factors Seroepidemiologic Studies Germany Health care medicine Seroprevalence Infection control Healthcare workers Humans 030212 general & internal medicine Longitudinal Studies Prospective Studies Young adult Prospective cohort study Secondary Care Centers 0105 earth and related environmental sciences Transmission (medicine) business.industry SARS-CoV-2 Public Health Environmental and Occupational Health COVID-19 Coronavirus Disease Hotspot Family medicine Immunoglobulin G Female business Cohort study |
| Zdroj: | International Journal of Hygiene and Environmental Health |
| ISSN: | 1618-131X 1438-4639 |
| Popis: | Purpose The objective of the ongoing study was to investigate how SARS-CoV-2 infection spread within two hospitals in North Rhine-Westphalia, Germany by testing the employees working in high-risk, intermediate-risk and low-risk-areas for the presence of SARS-CoV-2 IgG antibodies. Presented intermediate results evaluate the first infection period until the end of September 2020. Methods The study “COVID-19: Hotspot hospital?- Seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany " is a prospective, single centre observational cohort study conducted at the St. Vincenz Hospital Datteln with 316 beds. The presented data include one other hospital: St. Laurentius Stift Waltrop, Germany with 172 beds. Results Between June 2020 and September 2020 we analyzed serum samples of 907 employees which represents 62.1% of all employees. Thirteen employees (1.4%), respectively 13/696 healthcare workers (HCWs) (1.9%) had detectable SARS-CoV-2 IgG antibodies. Among them, 4 (30.8%) were aware of COVID-19 exposure, and 5 (38.5%) reported clinical symptoms. HCWs working in high-risk areas had a seroprevalence rate of 1.6% (1/64), HCWs working in intermediate-risk area 1.7% (11/632) and 0.5% employees (1/211) in low-risk areas with no contact to patients were seropositive. Conclusion Even if we treated COVID-19 positive patients, we found no clear evidence that infection was transmitted to HCWs in contact to these patients. As knowledge about SARS-CoV-2 transmission evolves, the concept of infection prevention must be continuously reviewed and adapted as needed to keep hospitals a safe place. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect